Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

Trial Profile

A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Baloxavir-marboxil (Primary) ; Oseltamivir; Peramivir; Zanamivir
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 18 Dec 2018 New source identified and integrated(European Clinical Trials Database record: EudraCT2018-001416-30)
    • 28 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 25 Oct 2018 Planned initiation date changed from 17 Oct 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top